Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Prevents organ rejection. Sold as Myfortic. Every FDA application for this active ingredient: 1 branded and 12 generic.
As of Nov 14, 2026, FDA lists 13 applications for Mycophenolate Sodium (sold as Myfortic), first approved Feb 27, 2004, with 0 new uses approved and 0 published complete response letters.
First approved: Feb 27, 2004
Applications: 13
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $33.0M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Mycophenolic Acid
Part D
$16.5M
-3%
17,220
Mycophenolic Acid
Part B
$15.3M
-15%
31,634
Myfortic
Part D
$1.3M
+21%
166
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
MYCOPHENOLATE 200 MG/ML SUSP: $0.915 per MLGeneric · -17% in a year
MYCOPHENOLATE 250 MG CAPSULE: $0.135 per unitGeneric · -2% in a year
MYCOPHENOLATE 500 MG TABLET: $0.253 per unitGeneric · -8% in a year
MYFORTIC 180 MG TABLET: $7.43 per unitBrand · +3% in a year
MYFORTIC 360 MG TABLET: $14.93 per unitBrand · +4% in a year
Clinical Trials
209 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA